雄激素剥夺治疗联合根治性局部治疗对比单纯雄激素剥夺治疗用于新诊断寡转移性前列腺癌:一项II期随机对照试验
这项开放标签随机对照试验纳入200例新诊断寡转移性前列腺癌患者,随机分配至雄激素剥夺治疗(ADT)组或ADT联合根治性局部治疗(RLT)组。中位随访-48个月时,联合治疗组影像学无进展生存期(rPFS)未达到,对照组为40个月(HR 0.43,95%CI 0.27-0.70;p=0.001);3年总生存率联合组88% vs 对照组70%(HR 0.44,95%CI 0.24-0.81;p=0.008)。结论认为ADT联合RLT(主要为前列腺切除术)可显著提高rPFS和OS。
要点
- 新诊断寡转移性前列腺癌(≤5处骨或盆腔外淋巴结转移、无内脏转移)患者随机接受ADT或ADT+RLT。
- 联合组中位rPFS未达到,对照组为40个月(HR 0.43,95%CI 0.27-0.70;p=0.001)。
- 联合组3年OS率88%,对照组70%(HR 0.44,95%CI 0.24-0.81;p=0.008)。
核心结论
- 新诊断寡转移性前列腺癌患者接受ADT联合RLT(主要为前列腺切除术)相比单纯ADT,影像学无进展生存率和总生存率显著更高。
研究设计与样本
- 开放标签随机对照试验,纳入新诊断寡转移性前列腺癌患者,定义为骨或盆腔外淋巴结转移≤5处且无内脏转移,共200例随机分配,每组100例。
主要发现
- 中位年龄68岁,诊断时中位PSA为99 ng/ml。
- 研究组96例接受RLT(85例根治性前列腺切除术和11例放疗),对照组17例最终接受RLT(15例根治性前列腺切除术和2例放疗)。
- 中位随访-48个月时,研究组中位rPFS未达到,对照组为40个月(HR 0.43,95%CI 0.27-0.70;p=0.001)。
- 3年OS率研究组为88%,对照组为70%(HR 0.44,95%CI 0.24-0.81;p=0.008)。
临床怎么用
- 作者结论认为,新诊断寡转移性前列腺癌患者接受ADT联合RLT(主要为前列腺切除术)相比单纯ADT,影像学无进展生存率和总生存率显著更高。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Previous studies suggested that men with metastatic prostate cancer might benefit from local treatment of the primary tumor. OBJECTIVE: To determine whether radical local therapy (RLT) improves survival for men with oligometastatic prostate cancer (OMPCa). DESIGN, SETTING, AND PARTICIPANTS: This open-label randomized controlled trial included patients with newly diagnosed OMPCa defined as five or fewer bone or extrapelvic lymph node metastases and no visceral metastases. INTERVENTION: Patients were randomly allocated to androgen deprivation therapy (ADT) or ADT and RLT. Men allocated RLT received either cytoreductive radical prostatectomy (RP) or prostate radiation therapy (RT) with a radical dose schedule. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The primary outcome was radiographic progression-free survival (rPFS). Secondary outcomes were overall survival (OS) and prostate-specific antigen (PSA) progression-free survival. RESULTS AND LIMITATIONS: Between September 2015 and March 2019, 200 patients were randomized, with 100 men allocated to each group. The median age was 68 yr and the median PSA at diagnosis was 99 ng/ml. In the study group, 96 patients underwent RLT (85 RP and 11 RT). In the control group, 17 patients eventually received RLT (15 RP and two RT). All patients were included for an intention-to-treat analysis. After a median follow-up of -48 mo, the median rPFS was not reached in the study group and was 40 mo in the control group (hazard ratio [HR] 0.43, 95% confidence interval [CI] 0.27-0.70; p = 0.001). The 3-yr OS rate was 88% for the study group and 70% for the control group (HR 0.44, 95% CI 0.24-0.81; p = 0.008). CONCLUSIONS: Men with newly diagnosed OMPCa who received ADT plus RLT (mainly prostatectomy) had significantly higher rates of rPFS and OS than those who received ADT alone. PATIENT SUMMARY: This study investigated the effect of radical local therapy (RLT) of the primary tumor on survival in patents with oligometastatic prostate cancer. In our group, RLT improved radiographic progression-free and overall survival.
引用
- Dai B, Zhang S, Wan FN, et al. Combination of Androgen Deprivation Therapy with Radical Local Therapy Versus Androgen Deprivation Therapy Alone for Newly Diagnosed Oligometastatic Prostate Cancer: A Phase II Randomized Controlled Trial. Eur Urol Oncol. 2022. PMID: 35780048. doi:10.1016/j.euo.2022.06.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。